Cas:75859-35-7 N-(1-phenylpropan-2-yl)aniline manufacturer & supplier

Chemical Name:N-(1-phenylpropan-2-yl)aniline

CAS.NO:75859-35-7

Synonyms:Benzeneethanamine,a-methyl-N-phenyl;N-Phenyl-1-methyl-2-phenylethylamine

Molecular Formula:C₁₅H₁₇N

Molecular Weight:211.30200

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:12.03000

Exact Mass:211.13600

LogP:3.80270

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like Benzeneethanamine,a-methyl-N-phenyl chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,N-Phenyl-1-methyl-2-phenylethylamine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,N-Phenyl-1-methyl-2-phenylethylamine Use and application,Benzeneethanamine,a-methyl-N-phenyl technical grade,usp/ep/jp grade.

Related News: In approving the first new Alzheimer’s drug in nearly 20 years, the U.S. Food and Drug Administration is taking its biggest risk yet with a strategy that allows new therapies onto the market without strong evidence that they work, regulatory and scientific experts say. N-(1-phenylpropan-2-yl)aniline manufacturer For Jefferies, this “has not been demonstrated to convincingly reduce Abeta plaque burden, in our view.” The firm forecasts $3 billion in global sales for gantenerumab, but at a striking 0%, “so probability so no contribution.” N-(1-phenylpropan-2-yl)aniline supplier For Jefferies, this “has not been demonstrated to convincingly reduce Abeta plaque burden, in our view.” The firm forecasts $3 billion in global sales for gantenerumab, but at a striking 0%, “so probability so no contribution.” N-(1-phenylpropan-2-yl)aniline vendor Since inception in 2004, ICIG has acquired 15 businesses, all of which have origins in major global chemical or pharmaceutical corporations and are independently managed. N-(1-phenylpropan-2-yl)aniline factory In 2016, in order to promote the innovative development, transformation and upgrading of the pharmaceutical industry, the Development and Reform Commission led the compilation of the Guiding Opinions on Promoting the Healthy Development of the Pharmaceutical Industry, which put forward requirements for all aspects of the medical industry and specifically proposed support for the field of chemical raw materials. .